Hi Darius, thank you very much for the in-depth analysis. Novo Nordisk is also attractively priced at the moment. How do you rate both stocks in comparison?
Hi Mike, I’m glad you enjoyed! You are absolutely right to point out Novo Nordisk. After the beating the stock has taken over the past year, it definitely looks attractive right now.
But for me, Pfizer and Novo are two very different beasts, and they represent two different types of bets. It's the classic difference between buying a great company at a fair price, and a fair company at a really great price.
With Novo, you are betting on a proven champion. They are one of only two leaders in the GLP-1 market with drugs like Ozempic and Wegovy that have changed the game. The problem is, the market knows this. Even after its fall, you're paying for that quality and the expectation of continued dominance.
The risks are clear and present: ferocious competition from Eli Lilly, pressure on pricing, and the immense challenge of maintaining massive growth. The stock is cheaper, yes, but it is far from unloved.
Pfizer, on the other hand, is a bet on deep-seated pessimism. As I laid out in the article, the market has essentially written the company off, focusing entirely on the post-COVID hangover. The valuation is pricing in stagnation, if not outright decline.
What you're buying with Pfizer isn't a flawless growth story; you're buying a transformation that nobody is paying attention to, at a price that provides a substantial margin of safety. That hefty dividend is the market paying you to wait for the story to play out.
So, it boils down to this: Do you want to bet on a turnaround story (Pfizer), or a fallen champion (Novo)? While the contrarian in me loves the deep value proposition at Pfizer, I also see a truly rare opportunity in Novo Nordisk. The market has, in my view, over-punished Novo for its recent stumbles - slowing growth and intensifying competition - creating a chance to buy a best-in-class company at a valuation that is now compelling.
Pfizer is spending tens of billions to try and build a presence in markets like obesity where Novo is already the undisputed leader. While Pfizer's path is one of transformation and hope, Novo's is one of defending its crown. After a near 65% collapse from its peak, the risks for Novo are now more than priced in, leaving you with the undisputed market leader, with a wide economic moat, at a fantastic discount.
For that reason, while I still really like Pfizer, I have more conviction in Novo Nordisk right now. However the beauty of the market is that you can own both!
I hope this helped, and let me know if I can answer any other questions you have.
Hi Darius, thank you very much for the in-depth analysis. Novo Nordisk is also attractively priced at the moment. How do you rate both stocks in comparison?
Hi Mike, I’m glad you enjoyed! You are absolutely right to point out Novo Nordisk. After the beating the stock has taken over the past year, it definitely looks attractive right now.
But for me, Pfizer and Novo are two very different beasts, and they represent two different types of bets. It's the classic difference between buying a great company at a fair price, and a fair company at a really great price.
With Novo, you are betting on a proven champion. They are one of only two leaders in the GLP-1 market with drugs like Ozempic and Wegovy that have changed the game. The problem is, the market knows this. Even after its fall, you're paying for that quality and the expectation of continued dominance.
The risks are clear and present: ferocious competition from Eli Lilly, pressure on pricing, and the immense challenge of maintaining massive growth. The stock is cheaper, yes, but it is far from unloved.
Pfizer, on the other hand, is a bet on deep-seated pessimism. As I laid out in the article, the market has essentially written the company off, focusing entirely on the post-COVID hangover. The valuation is pricing in stagnation, if not outright decline.
What you're buying with Pfizer isn't a flawless growth story; you're buying a transformation that nobody is paying attention to, at a price that provides a substantial margin of safety. That hefty dividend is the market paying you to wait for the story to play out.
So, it boils down to this: Do you want to bet on a turnaround story (Pfizer), or a fallen champion (Novo)? While the contrarian in me loves the deep value proposition at Pfizer, I also see a truly rare opportunity in Novo Nordisk. The market has, in my view, over-punished Novo for its recent stumbles - slowing growth and intensifying competition - creating a chance to buy a best-in-class company at a valuation that is now compelling.
Pfizer is spending tens of billions to try and build a presence in markets like obesity where Novo is already the undisputed leader. While Pfizer's path is one of transformation and hope, Novo's is one of defending its crown. After a near 65% collapse from its peak, the risks for Novo are now more than priced in, leaving you with the undisputed market leader, with a wide economic moat, at a fantastic discount.
For that reason, while I still really like Pfizer, I have more conviction in Novo Nordisk right now. However the beauty of the market is that you can own both!
I hope this helped, and let me know if I can answer any other questions you have.
All the best,
Darius
Thank you Darius for your prompt reply and explanation. It makes sense to me, and as you say, why not just own both. 🙂